News

Media

Conferences

Publications

Clinical

Events

Resources

From Tertiary Centers to Community Settings: Effective Implementation of Bispecific Antibody Therapies in Multiple Myeloma Care : Episode 2

Opinion

Video

November 25, 2024

Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Strategic sequencing of bispecific antibodies and CAR T-cell therapy is crucial for optimizing outcomes in RRMM treatment.
Operational challenges include coordinating multidisciplinary teams, managing toxicities, and ensuring timely access to therapies.
Streamlined communication and robust monitoring protocols are essential for addressing therapy-related challenges.
Enhancing logistical frameworks facilitates efficient delivery of advanced therapies, improving patient experience and therapeutic efficacy.

Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

Now Viewing

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

EP: 5.Resources and Education for Operationalizing Bispecifics

EP: 6.Safety Profiles of Bispecific Antibodies for RRMM

EP: 7.Preventing CRS and ICANS Across Sites of Care

EP: 8.Managing CRS and ICANS: Approaches and Protocols

EP: 9.Infection Prevention and Leveraging EHR for Bispecific Therapy Management

EP: 10.Navigating REMS Requirements and Educating Other Stakeholders on Bispecific Therapies

EP: 11.Administering Bispecifics in the Community vs Academic Centers

EP: 12.Improving Transitions of Care for Patients Receiving Bispecific Therapies and Final Recommendations

Video content above is prompted by the following:

How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!